The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 18, 2019

Filed:

Mar. 16, 2015
Applicant:

Mitsubishi Tanabe Pharma Corporation, Osaka-shi, Osaka, JP;

Inventors:

Roland Newman, San Diego, CA (US);

Steve Granger, Encinitas, CA (US);

Michael Lyman, San Diego, CA (US);

Dragan Grabulovski, Zurich, CH;

Richard Woods, Zurich, CH;

Michela Silacci, Zurich, CH;

Wenjuan Zha, Zurich, CH;

Isabella Attinger-Toller, Vancouver, CA;

Assignee:

MITSUBISHI TANABE PHARMA CORPORATION, Osaka-shi, Osaka, JP;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); C12N 9/12 (2006.01); C12N 15/62 (2006.01); C12N 9/96 (2006.01); C07K 16/24 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2866 (2013.01); C07K 16/244 (2013.01); C12N 9/12 (2013.01); C12N 9/1205 (2013.01); C12N 9/96 (2013.01); C12N 15/62 (2013.01); C12Y 207/01112 (2013.01); C12Y 207/10 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2318/20 (2013.01); C07K 2319/00 (2013.01); C07K 2319/33 (2013.01); C07K 2319/70 (2013.01);
Abstract

Provided is a bi-specific fusion polypeptide comprising a fynomer sequence that binds to interleukin-17a (IL-17a) and is conjugated to an antibody or subsequence thereof that binds to interleukin-6 receptor (IL-6R). The fusion polypeptide can bind to both IL-17a and IL-6R thereby suppresses, reduces, decreases, inhibits or blocks both IL-17a and IL-6R activities.


Find Patent Forward Citations

Loading…